Significance of dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expressions in hepatocellular carcinoma

Hepatology Research

Volumn 39, Issue 3, 2009, Pages 274-281

  Nii, Akira ^a   Shimada, Mitsuo ^a   Ikegami, Toru ^a   Harino, Yukari ^a   Imura, Satoru ^a   Morine, Yuji ^a   Kanemura, Hirofumi ^a   Arakawa, Yusuke ^a   Sugimoto, Koji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Dihydropyrimidine dehydrogenase; Hepatic resection; Hepatocellular carcinoma; Ki 67; Prognosis; Thymidylate synthase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; KI 67 ANTIGEN; MESSENGER RNA; THYMIDYLATE SYNTHASE;

ADULT; AGE; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME;

EID: 69249236864     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00457.x     Document Type: Article

References (39)

1. Okuda K. Hepatocellular carcinoma: Recent progress. Hepatology 1992; 15: 948-63.
2. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-35.
3. Damdinsuren B, Nagano H, Monden M. Combined intra-arterial 5-fluorouracil and subcutaneous interferon-alpha therapy for highly advanced hepatocellular carcinoma. Hepatol Res 2007; 37: 238-50.
4. Ogawa M, Yamamoto T, Kubo S et al. Clinicopathologic analysis of risk factors for distant metastasis of hepatocellular carcinoma. Hepatol Res 2004; 29: 228-34.
5. Kubo S, Tanaka H, Takemura S et al. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 2007; 37: 94-100.
6. Ikai I, Arii S, Okazaki M et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2007; 37: 676-91.
7. Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: Its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999; 5: 1947-9.
8. Kornmann M, Schwabe W, Sander S et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: Predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003; 15: 4116-24.
9. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203-6.
10. Lassmann S, Hennig M, Rosenberg R et al. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors -correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis 2006; 21: 238-47.
11. Fujiwaki R, Hata K, Nakayama K, Fukumoto M, Miyazaki K. Gene expression for dihydropyrimidine dehydrogenase influences outcome in epithelial ovarian cancer. J Clin Oncol 2000; 18: 3946-51.
12. Santini DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthase with 5-fluorodeoxyuridine. Biochemistry 1974; 13: 471-80.
13. Ceppi P, Volante M, Saviozzi S et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107: 1589-96.
14. Hotta T, Kobayashi Y, Taniguchi K et al. Thymidine phosphate and dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer. Oncol Rep 2004; 12: 347-51.
15. Baba H, Teramoto K, Kawamura T, Mori A, Imamura M, Arii S. Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers. Cancer Chemother Pharmacol 2003; 52: 469-76.
16. Takahashi T, Yoshida H, Mamada Y et al. Profiling of fluorouracil-related genes by microdissection technique in hepatocellular carcinoma. Hepatogastroenterology 2007; 54: 1612-6.
17. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Cancer, 2nd English edn. Tokyo: Kanehara, 2003.
18. Lord RV, Salonga D, Danenberg KD et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000; 4: 135-42.
19. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 986-94.
20. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6: 995-1011.
21. Ye CP, Qiu CZ, Huang ZX et al. Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma. World J Gastroenterl 2007; 13: 6264-8.
22. Hotta T, Taniguchi K, Kobayashi Y et al. Comparative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in gastric and colorectal cancers. Oncol Rep 2004; 11: 1045-51.
23. Yu Z, Sun J, Zhen J, Zhang Q, Yang Q. Thymidylate synthase predicts for clinical outcome in invasive breast cancer. Histol Histopathol 2005; 20: 871-8.
24. Johnson SJ, Ridge SA, Cassidy J, McLeod HL. Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res 1999; 5: 2566-70.
25. Heidelberger C. Cancer chemotherapy with purine and pyrimidine analogues. Annu Rev Pharm 1967; 7: 101-24.
26. Ebara M, Hatano R, Fukuda H, Yoshikawa M, Sugiura N, Saisho H. Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 3 0 patients. Hepatogastroenterology 1998; 3: 1214-20.
27. Krugluger W, Brandstaetter A, Kallay E et al. Regulation of genes of the circadian clock in human colon cancer: Reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. Cancer Res 2007; 67: 7917-22.
28. Tuchman M, O'Dea RF, Ramnaraine ML, Mirkin BL. Pyrimidine base degradation in cultured murine C-1300 neuroblastoma cells and in situ tumors. Cancer Res 1985; 45: 5553-6.
29. Williams CS, Tuchman M. Correlations of dihydropyrimidine dehydrogenase, thymidine phosphorylase and thymidine kinase activities in strongly and weakly malignant cultured murine neuroblastoma cells. Int J Cancer 1989; 43: 901-4.
30. Bjarnason GA, Jordan RC, Wood PA et al. Circadian expression of clock genes in human oral mucosa and skin. Am J Pathol 2001; 158: 1793-801.
31. Jiang H, Lu J, Ji J. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: A potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 2004; 141: 616-23.
32. Porsin B, Formento JL, Filipski E et al. Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: Comparison between enzyme activity and gene expression. Eur J Cancer 2003; 39: 822-8.
33. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000; 92: 994-1000.
34. Ichikawa W, Takahashi T, Suto K et al. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer 2004; 112: 967-73.
35. Ferninandus JA, Moris HP, Weber G. Behavior of opposing pathways of thymidine utilization in differentiating, regenerating, and neoplastic liver. Cancer Res 1971; 31: 550-6.
36. Lazarevich NL, Cheremnova OA, Varga EV et al. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 2004; 39: 1038-47.
37. Yoshida K, Tomita Y, Okuda Y et al. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 2006; 13: 159-67.
38. Lenz HJ, Danenberg KD, Leichman CG et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site. Clin Cancer Res 1998; 4: 1227-34.
39. Hashimoto Y, Shiotani T, Eble JN, Glover JL, Weber G. Increased thymidylate synthase activity in normal and neoplastic proliferation. Cancer Biochem Biophys 1988; 10: 1-10.